Molecular changes induced by the curcumin analogue D6 in human melanoma cells

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Rozzo, Carla ^a   Fanciulli, Manuela ^b   Fraumene, Cristina ^b   Corrias, Antonio ^a   Cubeddu, Tiziana ^b   Sassu, Ilaria ^a   Cossu, Sara ^a   Nieddu, Valentina ^a   Galleri, Grazia ^b   Azara, Emanuela ^a   Dettori, Maria Antonietta ^a   Fabbri, Davide ^a   Palmieri, Giuseppe ^a   Pisano, Marina ^a  

^a CNR   (Italy)

^b Porto Conte Ricerche Srl   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; DICHOLINE SUBERATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DENSITY; CELL GROWTH; CELL PROLIFERATION; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; DNA MODIFICATION; DOWN REGULATION; FIBROBLAST; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE INDUCTION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; MICROARRAY ANALYSIS; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PHASE TRANSITION; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CURCUMIN; FIBROBLASTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL; TRANSCRIPTION, GENETIC;

EID: 84876953494     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-37     Document Type: Article

References (58)

1. Berwick M, Erdei E, Hay J. Melanoma epidemiology and public health. Dermatol Clin 2009, 27:205-214. 10.1016/j.det.2008.12.002, 3595561, 19254665.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010. CA Cancer J Clin 2010, 60:277-300. 10.3322/caac.20073, 20610543.
3. Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology 2009, 23:488-496. 2737459, 19544689.
4. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AMM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, for the BRIM-3 Study Group Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516. 10.1056/NEJMoa1103782, 3549296, 21639808, for the BRIM-3 Study Group.
5. Ribas A, Flaherty KT. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol 2011, 8:426-433. 10.1038/nrclinonc.2011.69, 21606968.
6. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJM, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723. 10.1056/NEJMoa1003466, 3549297, 20525992.
7. Ascierto PA, Grimaldi AM, Curti B, Faries MB, Ferrone S, Flaherty K, Fox BA, Gajewski TF, Gershenwald JE, Gogas H, Grossmann K, Hauschild A, Hodi FS, Kefford R, Kirkwood JM, Leachmann S, Maio M, Marais R, Palmieri G, Morton DL, Ribas A, Stroncek DF, Stewart R, Wang E, Mozzillo N, Marincola FM. Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J. Transl Med 2012, 10:83. 10.1186/1479-5876-10-83, 3390271, 22551296.
8. Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 2006, 20:2149-2182. 10.1101/gad.1437206, 16912270.
9. Palmieri G, Capone M, Ascierto ML, Gentilcore G, Stroncek DF, Casula M, Sini MC, Palla M, Mozzillo N, Ascierto PA. Main roads to melanoma. J Trans Med 2009, 7:86:1-86:17.
10. Shanmugam MK, Kannaiyan R, Sethi G. Targeting cell signaling and apoptotic pathways by dietary agents: role in the prevention and treatment of cancer. Nutr Cancer 2011, 63:161-173. 10.1080/01635581.2011.523502, 21294053.
11. Jensen JD, Wing GJ, Dellavalle RP. Nutrition and melanoma prevention. Clin Dermatol 2010, 28:644-649. 10.1016/j.clindermatol.2010.03.026, 21034988.
12. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett 2008, 267:133-164. 10.1016/j.canlet.2008.03.025, 18462866.
13. Kunwar A, Barik A, Mishra B, Rathinasamy K, Pandey R, Priyadarsini KI. Quantitative cellular uptake, localization and cytotoxicity of curcumin in normal and tumor cells. Biochim Biophys Acta 2008, 1780:673-679. 10.1016/j.bbagen.2007.11.016, 18178166.
14. Gupta SC, Prasad S, Kim JH, Patchva S, Webb LJ, Priyadarsini IK, Aggarwal BB. Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep 2011, 28:1937-1955. 10.1039/c1np00051a, 3604998, 21979811.
15. Das T, Sa G, Saha B, Das K. Multifocal signal modulation therapy of cancer: ancient weapon, modern targets. Mol Cell Biochem 2010, 336:85-95. 10.1007/s11010-009-0269-0, 19826768.
16. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008, 269:199-225. 10.1016/j.canlet.2008.03.009, 18479807.
17. Bill MA, Bakan C, Benson DM, Fuchs J, Young G, Lesinski GB. Curcumin induces proapoptotic effects against human melanoma cells and modulates the cellular response to immunotherapeutic cytokines. Mol Cancer Ther 2009, 8:2726-2735. 10.1158/1535-7163.MCT-09-0377, 2748163, 19723881.
18. Lin CL, Lin JK. Curcumin: a potential cancer chemopreventive agent trough suppressing NF-kB signalling. J Cancer Mol 2008, 4:11-16.
19. Zheng M, Ekmekcioglu S, Walch ET, Tang CH, Grimm EA. Inhibition of nuclear factor-kappaB and nitric oxide by curcumin induces G2/M cell cycle arrest and apoptosis in human melanoma cells. Melanoma Res 2004, 14:165-171. 10.1097/01.cmr.0000129374.76399.19, 15179184.
20. Siwak DR, Shishodia S, Aggarwal BB, Kurzrock R. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer 2005, 104:879-890. 10.1002/cncr.21216, 16007726.
21. Pisano M, Pagnan G, Dettori MA, Cossu S, Caffa I, Sassu I, Emionite L, Fabbri D, Cilli M, Pastorino F, Palmieri G, Delogu G, Ponzoni M, Rozzo C. Enhanced anti-tumor activity of a new curcumin-related compound against melanoma and neuroblastoma cells. Mol Cancer 2010, 9:137:1-137:12.
22. Carr KM, Bittner M, Trent JM. Gene-expression profiling in human cutaneous melanoma. Oncogene 2003, 22:3076-3080. 10.1038/sj.onc.1206448, 12789283.
23. Hoek KS. DNA microarray analyses of melanoma gene expression: a decade in the mines. Pigment Cell Res 2007, 20:466-484. 10.1111/j.1600-0749.2007.00412.x, 17935490.
24. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006, 24:4340-4346. 10.1200/JCO.2006.06.2984, 16908931.
25. Oyadomari S, Mori M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ 2004, 11:381-389. 10.1038/sj.cdd.4401373, 14685163.
26. Yan M, Lee J, Schilbach S, Goddard A, Dixit V. mE10, a novel caspase recruitment domain-containing proapoptotic molecule. J Biol Chem 1999, 274:10287-10292. 10.1074/jbc.274.15.10287, 10187815.
27. McDonald ER, El-Deiry WS. Cell cycle control as a basis for cancer drug development. Int J Oncol 2000, 16:871-886.
28. Nollen EA, Morimoto RI. Chaperoning signaling pathways: molecular chaperones as stress-sensing 'heat shock' proteins. J Cell Sci 2002, 115:2809-2816.
29. Massé D, Ebstein F, Bougras G, Harb J, Meflah K, Grégoire M. Increased expression of inducible HSP70 in apoptotic cells is correlated with their efficacy for antitumor vaccine therapy. Int J Cancer 2004, 111:75-83.
30. Carta F, Demuro PP, Zanini C, Santona A, Castiglia D, D'Atri S, Ascierto PA, Napolitano M, Cossu A, Tadolini B, Turrini F, Manca A, Sini MC, Palmieri G, Rozzo C. Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases. Melanoma Res 2005, 15:235-244. 10.1097/00008390-200508000-00002, 16034300.
31. Oyadomari S, Araki E, Mori M. Endoplasmic reticulum stress mediated apoptosis in pancreatic beta-cells. Apoptosis 2002, 7:335-345. 10.1023/A:1016175429877, 12101393.
32. Noonan EJ, Place RF, Giardina C, Hightower LE. Hsp70B' regulation and function. Cell Stress Chaperones 2007, 12:219-229. 10.1379/CSC-278.1, 1971232, 17915554.
33. Scott DW, Loo G. Curcumin-induced GADD153 gene up-regulation in human colon cancer cells. Carcinogenesis 2004, 25:2155-2164. 10.1093/carcin/bgh239, 15271854.
34. Erol A. Deciphering the intricate regulatory mechanisms for the cellular choice between cell repair, apoptosis or senescence in response to damaging signals. Cell Signal 2011, 23:1076-1081. 10.1016/j.cellsig.2010.11.023, 21144894.
35. Aylon Y, Oren M. Living with p53, dying of p53. Cell 2007, 130:597-600. 10.1016/j.cell.2007.08.005, 17719538.
36. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009, 9:400-414. 10.1038/nrc2657, 2722839, 19440234.
37. Cretu A, Sha X, Tront J, Hoffman B, Liebermann DA. Stress sensor Gadd45 genes as therapeutic targets in cancer. Cancer Ther 2009, 7:268-276. 2696386, 19652693.
38. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T, Tanaka N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000, 288:1053-1058. 10.1126/science.288.5468.1053, 10807576.
39. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003, 36:131-149. 10.1046/j.1365-2184.2003.00266.x, 12814430.
40. Tamura RE, de Vasconcellos JF, Sarkar D, Liebermann TA, Fisher PB, Zerbini LF. GADD45 proteins: central players in tumorigenesis. Curr. Mol. Med 2012, 12:634-651. 10.2174/156652412800619978, 22515981.
41. Huang DCS, Strasser A. BH3-Only Proteins - Essential Initiators of Apoptotic Cell Death. Cell 2000, 103:839-842. 10.1016/S0092-8674(00)00187-2, 11136969.
42. Sullivan A, Lu X. ASPP: a new family of oncogenes and tumour suppressor genes. Br J Cancer 2007, 96:196-200. 10.1038/sj.bjc.6603525, 2359998, 17211478.
43. Bai C, Sen P, Hofmann K, Ma L, Goebl M, Harper JW, Elledge SJ. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell 1996, 86:263-274. 10.1016/S0092-8674(00)80098-7, 8706131.
44. Cardozo T, Pagano M. The SCF ubiquitin ligase: insights into a molecular machine. Nature Rev Mol Cell Biol 2004, 5:739-751.
45. D'Angiolella V, Donato V, Vijayakumar S, Saraf A, Florens L, Washburn MP, Dynlacht B, Pagano M. SCFCyclin F controls centrosome homeostasis and mitotic fidelity through CP110 degradation. Nature 2010, 466:138-142. 10.1038/nature09140, 2946399, 20596027.
46. Ashman LK. The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol 1999, 31:1037-1051. 10.1016/S1357-2725(99)00076-X, 10582338.
47. Davies MA. The role of the PI3K-AKT pathway in melanoma. Cancer J 2012, 18:142-147. 10.1097/PPO.0b013e31824d448c, 22453015.
48. Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 2009, 8:33-40. 10.1038/nrd2781, 2729321, 19116625.
49. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999, 401:82-85. 10.1038/43466, 10485710.
50. Kuttan G, Kumar KB, Guruvayoorappan C, Kuttan R. Antitumor, anti-invasion, and antimetastatic effects of curcumin. Adv Exp Med Biol 2007, 595:173-184. 10.1007/978-0-387-46401-5_6, 17569210.
51. Webster GA, Perkins ND. Transcriptional cross talk between NF-kappaB and p53. Mol Cell Biol 1999, 19:485-3495.
52. Iyer NG, Chin SF, Ozdag H, Daigo Y, Hu DE, Cariati M, Brindle K, Aparicio S, Caldas C. p300 regulates p53-dependent apoptosis after DNA damage in colorectal cancer cells by modulation of PUMA/p21 levels. Proc Natl Acad Sci U S A 2004, 101:7386-7391. 10.1073/pnas.0401002101, 409928, 15123817.
53. Sen GS, Mohanty S, Hossain DM, Bhattacharyya S, Banerjee S, Chakraborty J, Saha S, Ray P, Bhattacharjee P, Mandal D, Bhattacharya A, Chattopadhyay S, Das T, Sa G. Curcumin enhances the efficacy of chemotherapy by tailoring p65NFkappaB-p300 cross-talk in favor of p53-p300 in breast cancer. J Biol Chem 2011, 286:42232-42247. 10.1074/jbc.M111.262295, 3234918, 22013068.
54. Pisano M, Pagnan G, Loi M, Mura ME, Tilocca MG, Palmieri G, Fabbri D, Dettori MA, Delogu G, Ponzoni M, Rozzo C. Antiproliferative and pro-apoptotic activity of eugenol-related biphenyls on malignant melanoma cells. Mol Cancer 2007, 6:8:1-8:1.
55. Kunwar A, Barik A, Pandey R, Priyadarsini KI. Transport of liposomal and albumin loaded curcumin to living cells: an absorption and fluorescence spectroscopic study. Biochim Biophys Acta 2006, 1760:1513-1520. 10.1016/j.bbagen.2006.06.012, 16904830.
56. Van Gelder RN, von Zastrow ME, Yool A, Dement WC, Barchas JD, Eberwine JH. Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proc Natl Acad Sci U S A 1990, 87:1663-1667. 10.1073/pnas.87.5.1663, 53542, 1689846.
57. Wright GW, Simon RM. A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics 2003, 19:2448-2455. 10.1093/bioinformatics/btg345, 14668230.
58. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Met 2012, 9:671-675.